SCHEMBL3600713

SCHEMBL3600713

CCCc1nn(C)c(Oc2cc(O[C@@H](C)C(=O)O)c(Cl)cc2Cl)c1C=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.37
KDM4E B2RXH2 3/20 0.37
HSD17B10 Q99714 3/20 0.37
HPGD P15428 2/20 0.36
SMN1; SMN2 Q16637 4/20 0.34
GAA P10253 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
TSHR P16473 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33
RAB9A P51151 3/20 0.32
NPC1 O15118 2/20 0.32
PTGDR2 Q9Y5Y4 3/20 0.32
TERT O14746 2/20 0.31
PPARG P37231 1/20 0.31
MAPT P10636 1/20 0.31
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3610942 0.92 ALDH1A1 (0.37) ALDH1A1KDM4EHSD17B10HPGDSMN1; SMN2
SCHEMBL3600509 0.90 ALDH1A1 (0.36) ALDH1A1KDM4EHSD17B10HPGDSMN1; SMN2
SCHEMBL3600503 0.90 ALDH1A1 (0.36) ALDH1A1KDM4EHSD17B10HPGDSMN1; SMN2
SCHEMBL3609640 0.86 ALDH1A1 (0.41) ALDH1A1KDM4EHSD17B10HPGDSMN1; SMN2
SCHEMBL3597585 0.85 SMN1; SMN2 (0.48) ALDH1A1KDM4EHSD17B10HPGDSMN1; SMN2
SCHEMBL3611050 0.85 SMN1; SMN2 (0.48) ALDH1A1KDM4EHSD17B10HPGDSMN1; SMN2
SCHEMBL3611586 0.84 ALDH1A1 (0.41) ALDH1A1KDM4EHSD17B10HPGDSMN1; SMN2
SCHEMBL3606216 0.83 ALDH1A1 (0.37) ALDH1A1KDM4EHSD17B10HPGDSMN1; SMN2
SCHEMBL3612127 0.82 KDM4E (0.38) ALDH1A1KDM4EHSD17B10HPGDSMN1; SMN2
SCHEMBL3605241 0.82 ALDH1A1 (0.37) ALDH1A1KDM4EHSD17B10HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016396-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-21 US disclosed
EP-2128138-A1 PYRAZOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016396-A1 PYRAZOLE COMPOUND SLC5A1, SLC5A2, GLP1R ALDH1A1 365/4885KDM4E 2049/4885HSD17B10 390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.